Outlook Therapeutics Inc (OTLK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.44-4.98%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · OTLK
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||
| Revenues | — | 1.4 | — | — | — | — | — | 8.1 | 3.1 | 3.8 | 3.0 |
| Total Revenues | — | — | — | — | — | — | — | 8.1 | 3.1 | 3.8 | 3.0 |
| Cost of Revenues | — | 1.4 | — | — | — | — | — | — | — | — | — |
| Gross Profit | — | 0.1 | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | |||||||||||
| Selling, General & Admin | 36.0 | 39.9 | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 17.4 | 27.2 | 41.8 | 26.5 | 42.3 | 39.0 | 26.3 | 23.8 | 18.5 | 23.8 | 32.8 |
| Operating Income | (55.6) | (67.1) | (71.7) | (53.1) | (63.1) | (51.7) | (36.8) | (36.3) | (29.6) | (35.9) | (51.3) |
| Earnings from Continuing Operations | |||||||||||
| Interest Expense | — | — | 3.2 | — | — | — | 1.8 | 3.5 | 3.9 | 5.6 | 1.9 |
| Interest & Investment Income | — | 0.1 | 0.9 | 1.0 | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (64.0) | (75.4) | (59.0) | (66.0) | (53.2) | (38.5) | (37.9) | (33.7) | (38.3) | (53.2) |
| Income Tax Expense | — | (1.6) | 0.0 | 0.0 | 0.0 | 0.0 | (3.3) | (3.4) | (3.6) | 0.5 | 0.1 |
| Net Income | |||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | (1.3) |
| Net Income | (61.1) | (62.4) | (75.4) | (59.0) | (66.1) | (53.2) | (35.2) | (34.5) | (30.1) | (38.8) | (53.3) |
| Per Share | |||||||||||
| Basic EPS | (0.45) | (1.79) | (4.06) | (4.72) | (0.31) | (0.35) | (0.67) | — | (1.22) | (1.67) | — |
| Diluted EPS | (0.45) | (1.79) | (4.06) | (4.72) | (0.31) | (0.35) | (0.67) | — | (1.22) | (1.80) | — |
| Basic Weighted Avg Shares | 136.7 | 34.8 | 18.5 | 12.5 | 212.1 | 152.7 | 72.6 | — | 39.5 | 24.0 | — |
| Diluted Weighted Avg Shares | 136.7 | 34.8 | 18.5 | 12.5 | 212.1 | 152.7 | 72.6 | — | 39.5 | 24.0 | — |
| Supplemental | |||||||||||
| EBITDA | — | (66.9) | (71.6) | (53.1) | (62.9) | (51.5) | (36.3) | (32.9) | (26.6) | (33.2) | (49.0) |
| EBIT | (55.6) | (67.1) | (71.7) | (53.1) | (63.1) | (51.7) | (36.8) | (36.3) | (29.6) | (35.9) | (51.3) |
| Effective Tax Rate | — | — | — | -0.0% | -0.0% | -0.0% | 8.5% | 9.0% | 10.8% | -1.3% | -0.2% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.